Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant GEMOX versus surveillance after resection of biliary tract cancer
2008-004560-39Phase 3Completed
- Sponsor
- Unicancer
- Start
- Mar 2009
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine and oxaliplatin in biliary cancer, cholangiocarcinoma (CCA) and gallbladder cancer (2 arms), sponsored by Unicancer. Primary endpoint: Recurrence-free survival. Started Mar 2009; status: completed.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on 2008-004560-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004560-39.